However, there is controversy over PD-L1’s ability to predict the treatment response of nICT in ESCC patients, given that various trials have shown that EC patients can benefit from the combination of immunotherapy and chemotherapy, irrespective of PD-L1 expression levels (27, 28). The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.